ZA202400405B - Methods of treating neurological diseases - Google Patents
Methods of treating neurological diseasesInfo
- Publication number
- ZA202400405B ZA202400405B ZA2024/00405A ZA202400405A ZA202400405B ZA 202400405 B ZA202400405 B ZA 202400405B ZA 2024/00405 A ZA2024/00405 A ZA 2024/00405A ZA 202400405 A ZA202400405 A ZA 202400405A ZA 202400405 B ZA202400405 B ZA 202400405B
- Authority
- ZA
- South Africa
- Prior art keywords
- methods
- neurological diseases
- treating neurological
- treating
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221261P | 2021-07-13 | 2021-07-13 | |
| PCT/CN2022/105077 WO2023284710A1 (en) | 2021-07-13 | 2022-07-12 | Methods of treating neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202400405B true ZA202400405B (en) | 2025-03-26 |
Family
ID=84919904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2024/00405A ZA202400405B (en) | 2021-07-13 | 2024-01-11 | Methods of treating neurological diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240309089A1 (https=) |
| EP (1) | EP4370153A4 (https=) |
| JP (1) | JP2024527401A (https=) |
| KR (1) | KR20240042443A (https=) |
| CN (1) | CN117999096A (https=) |
| AU (1) | AU2022310081A1 (https=) |
| CA (1) | CA3225077A1 (https=) |
| MX (1) | MX2024000591A (https=) |
| WO (1) | WO2023284710A1 (https=) |
| ZA (1) | ZA202400405B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3710471A1 (en) * | 2017-11-16 | 2020-09-23 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| WO2024197258A1 (en) * | 2023-03-23 | 2024-09-26 | Klaritos, Inc | Methods of treating alzheimer's disease |
| WO2025190311A1 (en) * | 2024-03-12 | 2025-09-18 | Sinomab Bioscience Limited | Method of identifying anti-siglec antibodies possessing cis-trans converter properties, anti-siglec antibodies and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201203442D0 (en) * | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| US9066928B1 (en) * | 2012-12-04 | 2015-06-30 | University Of Kentucky Research Foundation | Method, composition, and kit useful for treatment of alzheimer's disease |
| AU2014305658A1 (en) * | 2013-08-05 | 2016-02-11 | St. Vincent's Institute Of Medical Research | An antibody therapy for amyloid beta disease |
| WO2017196432A1 (en) * | 2016-05-12 | 2017-11-16 | La Jolla Institute For Allergy And Immunology | Compositions and methods for diagnosing and treating neurodegenerative disease |
| EP3867280A4 (en) * | 2018-10-18 | 2022-11-09 | Sinomab Bioscience Limited | METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS |
| ES2821599A1 (es) * | 2019-10-24 | 2021-04-26 | Univ Del Pais Vasco / Euskal Herriko Unibertsitatea | Compuestos y metodos para el tratamiento de la enfermedad de alzheimer |
-
2022
- 2022-07-12 MX MX2024000591A patent/MX2024000591A/es unknown
- 2022-07-12 US US18/578,300 patent/US20240309089A1/en active Pending
- 2022-07-12 CA CA3225077A patent/CA3225077A1/en active Pending
- 2022-07-12 EP EP22841346.4A patent/EP4370153A4/en active Pending
- 2022-07-12 KR KR1020247004608A patent/KR20240042443A/ko active Pending
- 2022-07-12 WO PCT/CN2022/105077 patent/WO2023284710A1/en not_active Ceased
- 2022-07-12 JP JP2024501831A patent/JP2024527401A/ja active Pending
- 2022-07-12 AU AU2022310081A patent/AU2022310081A1/en active Pending
- 2022-07-12 CN CN202280061890.XA patent/CN117999096A/zh active Pending
-
2024
- 2024-01-11 ZA ZA2024/00405A patent/ZA202400405B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240042443A (ko) | 2024-04-02 |
| JP2024527401A (ja) | 2024-07-24 |
| WO2023284710A1 (en) | 2023-01-19 |
| EP4370153A1 (en) | 2024-05-22 |
| EP4370153A4 (en) | 2025-05-07 |
| MX2024000591A (es) | 2024-03-19 |
| CA3225077A1 (en) | 2023-01-19 |
| CN117999096A (zh) | 2024-05-07 |
| AU2022310081A1 (en) | 2024-02-01 |
| US20240309089A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288574A (en) | Oligonucleotides and methods for use in the treatment of neurological diseases | |
| ZA202400405B (en) | Methods of treating neurological diseases | |
| GB202020573D0 (en) | Novel methods of therapy | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| EP4213891A4 (en) | METHODS OF TREATING NEUROLOGICAL DISEASE | |
| EP4267196A4 (en) | TREATMENT OF NEUROLOGICAL DISEASES | |
| LT4103178T (lt) | Fabri ligos gydymo būdai | |
| IL315503A (en) | Treatment methods | |
| GB202020572D0 (en) | Novel methods of therapy | |
| IL320711A (en) | Treatment methods | |
| IL290892A (en) | Methods for treating vascular diseases | |
| IL321201A (en) | Methods for treating neurological disorders | |
| IL290250A (en) | Targeted gene therapy to treat neurological diseases | |
| GB202201824D0 (en) | Methods of treatment | |
| IL326065A (en) | Methods of treating medical conditions and diseases | |
| GB202201819D0 (en) | Methods of treatment | |
| GB202201825D0 (en) | Methods of treatment | |
| HK40109636A (en) | Methods of treating neurological diseases | |
| IL290351A (en) | Compositions and methods for the treatment of neurological diseases | |
| IL312155A (en) | A method for treating cancer | |
| GB202108485D0 (en) | Treatment of inflammatory conditions or diseases | |
| SI4313114T1 (sl) | Kombinirano zdravljenje možganske poškodbe | |
| IL325768A (en) | Methods for treating neurological diseases | |
| HK40117579A (en) | Methods of treating neurological disorders | |
| GB202306675D0 (en) | Methods of treatment of inflammatory diseases |